MétaCan
Menu
Back to cohort
Record W4404169684 · doi:10.1101/2024.11.08.24316949

Reliability of large language model knowledge across brand and generic cancer drug names

2024· preprint· en· W4404169684 on OpenAlexaff
Jack Gallifant, Shan Chen, Sandeep Jain, Pedro Moreira, Ümit Topaloĝlu, Hugo J.W.L. Aerts, Jeremy L. Warner, William La Cava, Danielle S. Bitterman

Bibliographic record

VenuemedRxiv · 2024
Typepreprint
Languageen
FieldComputer Science
TopicComputational Drug Discovery Methods
Canadian institutionsArtificial Intelligence in Medicine (Canada)
Fundersnot available
KeywordsReliability (semiconductor)Brand namesDrugComputer scienceNatural language processingBusinessMedicineAdvertisingPharmacologyPhysics

Abstract

fetched live from OpenAlex

Abstract Purpose To evaluate the performance and consistency of large language models (LLMs) across brand and generic oncology drug names in various clinical tasks, addressing concerns about potential fluctuations in LLM performance due to subtle phrasing differences that could impact patient care. Methods This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from the HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, 1,000 drug-drug interaction synthetic patient cases, and 2,438 immune-related adverse event (irAE) cases. LLMs were tested on drug name recognition, word association, drug-drug interaction (DDI) detection, and irAE diagnosis using both brand and generic drug names. Results LLMs demonstrated high accuracy in matching brand and generic names (GPT-4o: 97.38% for brand, 94.71% for generic, p < 0.0001). However, they showed significant inconsistencies in word association tasks. GPT-3.5-turbo-0125 exhibited biases favoring brand names for effectiveness (OR 1.43, p < 0.05) and being side-effect-free (OR 1.76, p < 0.05). DDI detection accuracy was poor across all models (<26%), with no significant differences between brand and generic names. Sentiment analysis revealed significant differences, particularly in GPT-3.5-turbo-0125 (brand mean 0.6703, generic mean 0.9482, p < 0.0001). Consistency in irAE diagnosis varied across models. Conclusions and Relevance Despite high proficiency in name-matching, LLMs exhibit inconsistencies when processing brand versus generic drug names in more complex tasks. These findings highlight the need for increased awareness, improved robustness assessment methods, and the development of more consistent systems for handling nomenclature variations in clinical applications of LLMs. Context Summary Key objective This study aimed to assess the consistency of large language models (LLMs) in handling brand and generic oncology drug names across various tasks, including drug-drug interaction detection and adverse event identification. Knowledge generated LLMs demonstrated high accuracy in matching brand and generic names but showed significant inconsistencies in more complex tasks. Notable, models exhibited significant differences in attributing brand versus generic names to positive terms and sentiment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.025
metaresearch head score (Gemma)0.098
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.025
Threshold uncertainty score0.131

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0250.098
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0030.004
Open science0.0020.003
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.370
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venuemedRxivSame topicComputational Drug Discovery MethodsFrench-language works237,207